These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Comparative in vitro activity of glycopeptides against coagulase negative staphylococci isolated in pediatric hospital units]. Bourgeois F; Bingen E; Lambert-Zechovsky N Pathol Biol (Paris); 1992 Jan; 40(1):36-9. PubMed ID: 1533278 [TBL] [Abstract][Full Text] [Related]
7. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Goldstein FW; Coutrot A; Sieffer A; Acar JF Antimicrob Agents Chemother; 1990 May; 34(5):899-900. PubMed ID: 2141780 [TBL] [Abstract][Full Text] [Related]
8. Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance. Del Bene VE; John JF; Twitty JA; Lewis JW J Infect Dis; 1986 Aug; 154(2):349-52. PubMed ID: 2941491 [No Abstract] [Full Text] [Related]
9. In vitro antistaphylococcal activity of teicoplanin and ciprofloxacin in peritoneal dialysis effluent. Guay D; Klicker R; Pence T; Peterson P Eur J Clin Microbiol; 1986 Dec; 5(6):661-3. PubMed ID: 2948820 [No Abstract] [Full Text] [Related]
10. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. Biavasco F; Giovanetti E; Montanari MP; Lupidi R; Varaldo PE J Antimicrob Chemother; 1991 Jan; 27(1):71-9. PubMed ID: 1828799 [TBL] [Abstract][Full Text] [Related]
11. Glycopeptide resistance in Staphylococcus haemolyticus during treatment with teicoplanin. Blans M; Troelstra A Infect Control Hosp Epidemiol; 2001 May; 22(5):263-4. PubMed ID: 11428432 [No Abstract] [Full Text] [Related]
12. Emergence of teicoplanin-resistant coagulase-negative staphylococci. Cercenado E; García-Leoni ME; Díaz MD; Sánchez-Carrillo C; Catalán P; De Quirós JC; Bouza E J Clin Microbiol; 1996 Jul; 34(7):1765-8. PubMed ID: 8784585 [TBL] [Abstract][Full Text] [Related]
14. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp. O'Hare MD; Felmingham D; Grüneberg RN Drugs Exp Clin Res; 1988; 14(10):617-9. PubMed ID: 2977587 [TBL] [Abstract][Full Text] [Related]
15. Antistaphylococcal activity of teicoplanin in Riyadh, Saudi Arabia. Shibl AM; Ishag AH; Durgham SM APMIS Suppl; 1988; 3():68-70. PubMed ID: 2972301 [TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of teicoplanin and vancomycin against United States teicoplanin clinical trial isolates of gram-positive cocci. Kenny MT; Dulworth JK; Brackman MA Diagn Microbiol Infect Dis; 1991; 14(1):29-31. PubMed ID: 1826479 [TBL] [Abstract][Full Text] [Related]
17. [In vitro susceptibilities of clinical isolates of coagulase-negative staphylococci to glycopeptide antibiotics]. Kato D; Hanaki H; Cui L; Oguri T; Hiramatsu K Jpn J Antibiot; 1998 Dec; 51(12):735-45. PubMed ID: 10077772 [TBL] [Abstract][Full Text] [Related]
18. In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis. Herwaldt L; Boyken L; Pfaller M Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1007-12. PubMed ID: 1802693 [TBL] [Abstract][Full Text] [Related]
19. Heterogeneous resistance to vancomycin in Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus warneri clinical strains: characterisation of glycopeptide susceptibility profiles and cell wall thickening. Nunes AP; Teixeira LM; Iorio NL; Bastos CC; de Sousa Fonseca L; Souto-Padrón T; dos Santos KR Int J Antimicrob Agents; 2006 Apr; 27(4):307-15. PubMed ID: 16542825 [TBL] [Abstract][Full Text] [Related]
20. Changing susceptibilities of coagulase-negative staphylococci to teicoplanin in a teaching hospital. Sloos JH; van de Klundert JA; Dijkshoorn L; van Boven CP J Antimicrob Chemother; 1998 Dec; 42(6):787-91. PubMed ID: 10052903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]